In patients with Parkinson's Disease, SVZ proliferation is markedly reduced [417], a side effect of loss of dopaminergic innervations related to the stimulatory activity of dopamine on EGF and CNTF secretion by SVZ NSCs [418]. Here, EGF is linked to Parkinson disease.